These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 16448441)

  • 21. Pituitary apoplexy of a gonadotroph adenoma following gonadotrophin releasing hormone agonist therapy for prostatic cancer.
    Reznik Y; Chapon F; Lahlou N; Deboucher N; Mahoudeau J
    J Endocrinol Invest; 1997 Oct; 20(9):566-8. PubMed ID: 9413812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
    Smith MR; Zietman AL; Finkelstein JS; Wu CL
    N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
    [No Abstract]   [Full Text] [Related]  

  • 23. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
    Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
    Nishimura K; Arichi N; Tokugawa S; Yoshioka I; Kishikawa H; Ichikawa Y
    Int J Urol; 2007 Mar; 14(3):264-7. PubMed ID: 17430272
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of gonadotropin-releasing hormone agonists on bone metabolism markers and bone mineral density in patients with prostate cancer.
    Miyaji Y; Saika T; Yamamoto Y; Kusaka N; Arata R; Ebara S; Nasu Y; Tsushima T; Kumon H
    Urology; 2004 Jul; 64(1):128-31. PubMed ID: 15245949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypersensitivity vasculitis associated with leuprolide (Lupron).
    Gnanaraj J; Saif MW
    Cutan Ocul Toxicol; 2010 Sep; 29(3):224-7. PubMed ID: 20470239
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Luteinizing hormone-releasing hormone for prostate cancer in a hemodialysis patient: a case report].
    Mizusawa H; Kontani K; Okaneya T; Yoneyama T
    Hinyokika Kiyo; 1997 Jun; 43(6):421-3. PubMed ID: 9250492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Characteristics, effects, side effects of the LH-RH agonist].
    Miyanaga N; Akaza H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():177-81. PubMed ID: 12599567
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up.
    Akaza H; Homma Y; Usami M; Hirao Y; Tsushima T; Okada K; Yokoyama M; Ohashi Y; Aso Y;
    BJU Int; 2006 Sep; 98(3):573-9. PubMed ID: 16925756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advanced prostate cancer with extremely low prostate-specific antigen value at diagnosis: an example of high dose hook effect.
    Akamatsu S; Tsukazaki H; Inoue K; Nishio Y
    Int J Urol; 2006 Jul; 13(7):1025-7. PubMed ID: 16882082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship between hot flashes and distress in men receiving androgen deprivation therapy for prostate cancer.
    Ulloa EW; Salup R; Patterson SG; Jacobsen PB
    Psychooncology; 2009 Jun; 18(6):598-605. PubMed ID: 18942660
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Apoplexy of clinically silent pituitary adenoma during prostate cancer treatment with LHRH analog.
    Błaut K; Wiśniewski P; Syrenicz A; Sworczak K
    Neuro Endocrinol Lett; 2006 Oct; 27(5):569-72. PubMed ID: 17159826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Time to normalization of testosterone after withdrawal of long time LH-RH agonist therapy in prostate cancer].
    Kaku H; Tsushima T; Nasu Y; Kumon H
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():182-7. PubMed ID: 12599568
    [No Abstract]   [Full Text] [Related]  

  • 34. Twenty-five year evolution of medical hormonal therapy for prostate cancer.
    Moul JW
    BJU Int; 2009 Jan; 103(2):145-6. PubMed ID: 19278531
    [No Abstract]   [Full Text] [Related]  

  • 35. Penile length changes in men treated with androgen suppression plus radiation therapy for local or locally advanced prostate cancer.
    Haliloglu A; Baltaci S; Yaman O
    J Urol; 2007 Jan; 177(1):128-30. PubMed ID: 17162022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer.
    Hatoum HT; Crawford ED; Nielsen SK; Lin SJ; Marshall DC
    Expert Rev Pharmacoecon Outcomes Res; 2013 Apr; 13(2):261-70. PubMed ID: 23570437
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delayed pituitary apoplexy in patient with advanced prostate cancer treated with gonadotrophin-releasing hormone agonists.
    Sinnadurai M; Cherukuri RK; Moses RG; Nasser E
    J Clin Neurosci; 2010 Sep; 17(9):1201-3. PubMed ID: 20605467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gonadotropin-releasing hormone agonist failure in a man with prostate cancer.
    Smith MR; McGovern FJ
    J Urol; 2001 Jul; 166(1):211. PubMed ID: 11435862
    [No Abstract]   [Full Text] [Related]  

  • 40. Can androgen deprivation with leuprolide be predicted from histology alone? If not, why not?
    Drew PA; Murphy WM; Kubilis PS; Areford M
    J Urol; 1997 Jun; 157(6):2201-5. PubMed ID: 9146615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.